Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain.
CpG oligodeoxynucleotides (CpG-ODNs)
Fc receptors
Toll-like receptor 9 (TLR9)
macrophages
ovarian cancer
programmed cell death 1 (PD-1)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
received:
12
06
2021
revised:
26
07
2021
accepted:
03
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
A combination of TLR9 agonists and an anti-PD-1 antibody has been reported to be effective in immunocompetent mice but the role of innate immunity has not yet been completely elucidated. Therefore, we investigated the contribution of the innate immune system to this combinatorial immunotherapeutic regimens using an immunodeficient mouse model in which the effector functions of innate immunity can clearly emerge without any interference from T lymphocytes. Athymic mice xenografted with IGROV-1 human ovarian cells, reported to be sensitive to TLR9 agonist therapy, were treated with cytosine-guanine (CpG)-oligodeoxynucleotides (ODNs), an anti-PD-1 antibody or their combination. We found that PD-1 blockade dampened CpG-ODN antitumor activity. In vitro studies indicated that the interaction between the anti-PD-1 antibody fragment crystallizable (Fc) domain and macrophage Fc receptors caused these immune cells to acquire an immunoregulatory phenotype, contributing to a decrease in the efficacy of CpG-ODNs. Accordingly, in vivo macrophage depletion abrogated the detrimental effect exerted by the anti-PD-1 antibody. Our data suggest that if TLR signaling is active in macrophages, coadministration of an anti-PD-1 antibody can reprogram these immune cells towards a polarization state able to negatively affect the immune response and eventually promote tumor growth.
Sections du résumé
BACKGROUND
BACKGROUND
A combination of TLR9 agonists and an anti-PD-1 antibody has been reported to be effective in immunocompetent mice but the role of innate immunity has not yet been completely elucidated. Therefore, we investigated the contribution of the innate immune system to this combinatorial immunotherapeutic regimens using an immunodeficient mouse model in which the effector functions of innate immunity can clearly emerge without any interference from T lymphocytes.
METHODS
METHODS
Athymic mice xenografted with IGROV-1 human ovarian cells, reported to be sensitive to TLR9 agonist therapy, were treated with cytosine-guanine (CpG)-oligodeoxynucleotides (ODNs), an anti-PD-1 antibody or their combination.
RESULTS
RESULTS
We found that PD-1 blockade dampened CpG-ODN antitumor activity. In vitro studies indicated that the interaction between the anti-PD-1 antibody fragment crystallizable (Fc) domain and macrophage Fc receptors caused these immune cells to acquire an immunoregulatory phenotype, contributing to a decrease in the efficacy of CpG-ODNs. Accordingly, in vivo macrophage depletion abrogated the detrimental effect exerted by the anti-PD-1 antibody.
CONCLUSION
CONCLUSIONS
Our data suggest that if TLR signaling is active in macrophages, coadministration of an anti-PD-1 antibody can reprogram these immune cells towards a polarization state able to negatively affect the immune response and eventually promote tumor growth.
Identifiants
pubmed: 34439233
pii: cancers13164081
doi: 10.3390/cancers13164081
pmc: PMC8391891
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 20554
Références
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Cancer Res. 2018 Sep 1;78(17):4943-4956
pubmed: 29945961
Exp Mol Med. 2013 Feb 22;45:e11
pubmed: 23429360
J Ovarian Res. 2015 Aug 19;8:58
pubmed: 26282935
BMC Immunol. 2013 Feb 05;14:6
pubmed: 23384230
Sci Adv. 2020 Sep 18;6(38):
pubmed: 32948597
STAR Protoc. 2020 Dec 31;2(1):100246
pubmed: 33458708
Scand J Immunol. 2015 Feb;81(2):102-9
pubmed: 25410403
Oncoimmunology. 2017 Mar 3;6(4):e1299301
pubmed: 28507807
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Nat Rev Microbiol. 2018 Mar;16(3):143-155
pubmed: 29332945
Nat Med. 2010 Apr;16(4):452-9
pubmed: 20208540
Eur J Immunol. 2021 Jun;51(6):1473-1481
pubmed: 33684223
J Immunother Cancer. 2019 Nov 26;7(1):323
pubmed: 31771649
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Br J Pharmacol. 2020 Jan;177(2):328-345
pubmed: 31621898
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
JCI Insight. 2017 Sep 21;2(18):
pubmed: 28931759
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
Contemp Oncol (Pozn). 2018 Mar;22(1A):56-60
pubmed: 29628795
J Exp Clin Cancer Res. 2020 Nov 9;39(1):236
pubmed: 33168050
Front Oncol. 2014 Jun 06;4:137
pubmed: 24936477
J Immunother. 2010 Jan;33(1):8-15
pubmed: 19952960
Cell. 2020 Mar 19;180(6):1044-1066
pubmed: 32164908
Clin Cancer Res. 2008 Sep 1;14(17):5512-8
pubmed: 18765543
Comput Struct Biotechnol J. 2019 May 23;17:661-674
pubmed: 31205619
Cell Rep. 2018 Jul 10;24(2):379-390.e6
pubmed: 29996099
Neurobiol Dis. 2019 Apr;124:14-28
pubmed: 30389403
J Immunother. 2010 Apr;33(3):225-35
pubmed: 20445343
J Vis Exp. 2010 Jan 28;(35):
pubmed: 20110936
Cancer Res. 2011 Aug 15;71(16):5393-9
pubmed: 21724589
Protein Cell. 2021 May;12(5):426-435
pubmed: 33296049
Cell Oncol (Dordr). 2020 Aug;43(4):515-538
pubmed: 32418122
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Cancer Res. 2011 Oct 15;71(20):6382-90
pubmed: 21878529
Biochem J. 2017 May 16;474(11):1823-1836
pubmed: 28512250
Nat Commun. 2021 Jan 12;12(1):301
pubmed: 33436596
Antioxid Redox Signal. 2017 Jun 20;26(18):1023-1043
pubmed: 27397579
Cancer Discov. 2016 May;6(5):546-59
pubmed: 26928313
Cancer Res. 2017 Dec 1;77(23):6667-6678
pubmed: 28993412
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10483-8
pubmed: 18641123
Oncogene. 2017 Nov 2;36(44):6143-6153
pubmed: 28692048
Immunobiology. 2018 Jan;223(1):101-111
pubmed: 29032836
Adv Exp Med Biol. 2021;1290:51-65
pubmed: 33559854
Clin Cancer Res. 2013 Mar 1;19(5):1035-43
pubmed: 23460534
Cell Immunol. 2017 Mar;313:52-58
pubmed: 28089340
J Leukoc Biol. 2019 Aug;106(2):345-358
pubmed: 30576000
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
J Immunol. 2012 Aug 15;189(4):1792-9
pubmed: 22786766
Cell Mol Life Sci. 2020 Jul;77(14):2739-2749
pubmed: 31974656
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Cancer Cell. 2015 Sep 14;28(3):285-95
pubmed: 26373277
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
Target Oncol. 2018 Oct;13(5):583-598
pubmed: 30229471
Pathogens. 2020 Feb 20;9(2):
pubmed: 32093173
Front Immunol. 2020 May 29;11:1075
pubmed: 32547560
Cell Death Dis. 2020 Nov 19;11(11):993
pubmed: 33214550
J Immunol. 2015 Sep 15;195(6):2818-28
pubmed: 26276870
Annu Rev Pathol. 2020 Jan 24;15:493-518
pubmed: 31675482
Hum Vaccin Immunother. 2019;15(5):1111-1122
pubmed: 30888929
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
J Transl Med. 2013 Jan 29;11:25
pubmed: 23360557
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Sci Rep. 2019 Aug 16;9(1):11957
pubmed: 31420591